CIZ1B Biomarker Blood Test
Early Detection of Lung Cancer
Clinical ValidationActive
Key Facts
Indication
Early Detection of Lung Cancer
Phase
Clinical Validation
Status
Active
Company
About cizzle-biotechnology
Cizzle Biotechnology is on a mission to transform lung cancer survival rates through early detection. The company's core innovation is a simple blood test that detects the CIZ1B biomarker with high sensitivity, offering a more accessible and affordable alternative to current CT scan-based screening. Publicly listed and backed by research from the University of York, Cizzle is progressing through clinical validation and building partnerships to commercialize its life-saving diagnostic technology globally.
View full company profile